Clinical Trials Directory

Trials / Unknown

UnknownNCT01921699

Macrophages Effect on Chemoresistance

Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
2 (estimated)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Macrophages are derived from monocytes recruited to the tumor site and stimulated by specific chemokines secreted by tumor cells. These tumor associated macrophages (TAMs) have been postulated as being involved in the progression of cancer. Based on our preliminary findings and on published data we hypothesized that macrophage-induced chemoresistance (MIC) can promote survival of pancreatic carcinoma cells during chemotherapy. The overall goal of this study is to evaluate the mechanism of MIC in an in-vitro model of Pancreatic ductal adenocarcinoma (PDA). methods: 1. The human PDA cell line Panc1 will be grown in suitable conditions. 2. Macrophages will be produced by incubating mononuclear cells from the blood of healthy donors in medium with M-CSF for 7 days. 3. TAMs will be generated by culturing these macrophages with tumor-culture conditioning medium (TCCM) of PDA Cells for an additional 72 hours. 4. Human pancreatic cells (PANC1) will be treated with gemcitabine following exposure to macrophages CM. 5. Cell proliferation will be quantified by light microscopy and by an XTT Cell Proliferation Assay Kit.

Conditions

Interventions

TypeNameDescription
PROCEDUREtaking blood samples from healthy people

Timeline

Start date
2013-08-01
Primary completion
2013-09-01
First posted
2013-08-13
Last updated
2013-08-13

Source: ClinicalTrials.gov record NCT01921699. Inclusion in this directory is not an endorsement.